| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 60687-0844-65 | 60687-0844 | Hydrocortisone | Hydrocortisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 21, 2024 | Sep 21, 2024 | In Use |
| 16714-0816-02 | 16714-0816 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jun 1, 2018 | Nov 30, 2025 | No Longer Used |
| 60687-0844-21 | 60687-0844 | Hydrocortisone | Hydrocortisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 18, 2025 | In Use | |
| 00245-0825-30 | 00245-0825 | Everolimus | TORPENZ | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 24, 2024 | In Use | |
| 72579-0017-01 | 72579-0017 | Sonrotoclax | BEQALZI | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Aug 31, 2026 | In Use | |
| 73043-0040-01 | 73043-0040 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 31, 2026 | In Use | |
| 68788-8651-03 | 68788-8651 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 29, 2024 | In Use | |
| 68788-8212-08 | 68788-8212 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 7, 2022 | In Use | |
| 71205-0741-28 | 71205-0741 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 6, 2023 | In Use | |
| 10631-0118-31 | 10631-0118 | Isotretinoin | Absorica | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jun 8, 2012 | In Use | |
| 21695-0365-16 | 21695-0365 | Prednisolone | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 27, 2003 | In Use | |
| 61919-0733-90 | 61919-0733 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 18, 2019 | In Use | |
| 72205-0178-21 | 72205-0178 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 63020-0080-02 | 63020-0080 | Ixazomib | Ninlaro | 4.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov 20, 2015 | Oct 31, 2023 | No Longer Used |
| 72205-0178-91 | 72205-0178 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 71335-2972-03 | 71335-2972 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 29, 2025 | In Use | |
| 71335-2972-04 | 71335-2972 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 29, 2025 | In Use | |
| 43063-0703-21 | 43063-0703 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 17, 2016 | May 1, 2026 | No Longer Used |
| 55289-0438-42 | 55289-0438 | Prednisone | Prednisone | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 4, 1985 | Aug 29, 2014 | No Longer Used | |
| 68071-3958-03 | 68071-3958 | PREDNISONE | PREDNISONE | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 16, 2026 | In Use | |
| 72143-0252-30 | 72143-0252 | ISOTRETINOIN | ACCUTANE | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Aug 1, 2022 | In Use | |
| 69097-0036-81 | 69097-0036 | Pomalidomide | Pomalidomide | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Aug 30, 2026 | In Use | |
| 31722-0770-32 | 31722-0770 | Pomalidomide | Pomalidomide | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 50242-0140-86 | 50242-0140 | Vismodegib | Erivedge | 150.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Apr 9, 2013 | In Use | |
| 00093-0782-56 | 00093-0782 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Feb 21, 2003 | May 31, 2018 | No Longer Used |
Found 12611 results — Export these results
Home